Mizuho Boosts Jazz Pharmaceuticals (JAZZ) Price Target to $150.00
Jazz Pharmaceuticals (NASDAQ:JAZZ) had its target price upped by Mizuho from $144.00 to $150.00 in a research note published on Tuesday morning, Marketbeat reports. The firm currently has a neutral rating on the specialty pharmaceutical company’s stock.
JAZZ has been the topic of several other research reports. UBS dropped their price objective on Jazz Pharmaceuticals from $172.00 to $168.00 and set a buy rating on the stock in a research note on Wednesday, November 8th. Janney Montgomery Scott restated a buy rating and issued a $192.00 price objective (up previously from $180.00) on shares of Jazz Pharmaceuticals in a research note on Wednesday, August 9th. Morgan Stanley began coverage on Jazz Pharmaceuticals in a research note on Thursday, October 5th. They issued an equal weight rating and a $155.00 price objective on the stock. Cantor Fitzgerald restated a buy rating and issued a $200.00 price objective on shares of Jazz Pharmaceuticals in a research note on Sunday, December 3rd. Finally, Deutsche Bank set a $175.00 price objective on Jazz Pharmaceuticals and gave the company a buy rating in a research note on Wednesday, August 9th. Two investment analysts have rated the stock with a sell rating, five have assigned a hold rating and nineteen have issued a buy rating to the company. The stock has an average rating of Buy and a consensus price target of $181.28.
Jazz Pharmaceuticals (NASDAQ:JAZZ) traded up $1.17 during trading hours on Tuesday, reaching $134.83. The company’s stock had a trading volume of 243,100 shares, compared to its average volume of 506,948. The company has a quick ratio of 2.94, a current ratio of 3.10 and a debt-to-equity ratio of 0.63. The company has a market capitalization of $8,012.98, a price-to-earnings ratio of 16.77, a price-to-earnings-growth ratio of 0.86 and a beta of 0.98. Jazz Pharmaceuticals has a 12-month low of $99.53 and a 12-month high of $163.75.
In related news, CEO Bruce C. Cozadd sold 1,000 shares of the stock in a transaction that occurred on Tuesday, September 12th. The stock was sold at an average price of $153.52, for a total transaction of $153,520.00. The sale was disclosed in a filing with the SEC, which is accessible through this link. Also, Director Patrick G. Enright sold 352 shares of the stock in a transaction that occurred on Friday, November 17th. The stock was sold at an average price of $133.19, for a total value of $46,882.88. Following the sale, the director now directly owns 1,365 shares in the company, valued at approximately $181,804.35. The disclosure for this sale can be found here. Insiders sold 10,352 shares of company stock worth $1,417,763 in the last ninety days. 4.30% of the stock is owned by company insiders.
A number of large investors have recently modified their holdings of JAZZ. Toronto Dominion Bank grew its position in Jazz Pharmaceuticals by 12.4% during the second quarter. Toronto Dominion Bank now owns 736 shares of the specialty pharmaceutical company’s stock worth $114,000 after buying an additional 81 shares in the last quarter. US Bancorp DE grew its position in Jazz Pharmaceuticals by 94.4% during the second quarter. US Bancorp DE now owns 758 shares of the specialty pharmaceutical company’s stock worth $118,000 after buying an additional 368 shares in the last quarter. Gargoyle Investment Advisor L.L.C. acquired a new stake in Jazz Pharmaceuticals during the second quarter worth approximately $206,000. Advisor Group Inc. grew its position in Jazz Pharmaceuticals by 62.4% during the third quarter. Advisor Group Inc. now owns 1,431 shares of the specialty pharmaceutical company’s stock worth $210,000 after buying an additional 550 shares in the last quarter. Finally, Janney Montgomery Scott LLC acquired a new stake in Jazz Pharmaceuticals during the second quarter worth approximately $211,000. 91.30% of the stock is currently owned by institutional investors and hedge funds.
About Jazz Pharmaceuticals
Jazz Pharmaceuticals, Inc is a specialty pharmaceutical company focusing on the development and commercialization of pharmaceutical products to meet unmet medical needs in neurology and psychiatry. As of December 31, 2009, the Company markets two products: Xyrem (sodium oxybate) for the treatment of both cataplexy and excessive daytime sleepiness in patients with narcolepsy; and Luvox CR (fluvoxamine maleate) for the treatment of both obsessive compulsive disorder and social anxiety disorder.
Receive News & Ratings for Jazz Pharmaceuticals PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Jazz Pharmaceuticals PLC and related companies with MarketBeat.com's FREE daily email newsletter.